These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34149005)

  • 1. Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan.
    Huang YS; Tseng SY; Chang TE; Perng CL; Huang YH
    Pharmacogenet Genomics; 2021 Dec; 31(9):200-206. PubMed ID: 34149005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients.
    Kagaya H; Miura M; Niioka T; Saito M; Numakura K; Habuchi T; Satoh S
    Antimicrob Agents Chemother; 2012 Feb; 56(2):825-9. PubMed ID: 22106207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.
    Pirmohamed M; Alfirevic A; Vilar J; Stalford A; Wilkins EG; Sim E; Park BK
    Pharmacogenetics; 2000 Nov; 10(8):705-13. PubMed ID: 11186133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
    Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
    Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
    Ng CS; Hasnat A; Al Maruf A; Ahmed MU; Pirmohamed M; Day CP; Aithal GP; Daly AK
    Eur J Clin Pharmacol; 2014 Sep; 70(9):1079-86. PubMed ID: 24888881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.
    Hou ZD; Xiao ZY; Gong Y; Zhang YP; Zeng QY
    BMC Pharmacol Toxicol; 2014 Nov; 15():64. PubMed ID: 25413361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of NAT2 genotype to anti-tuberculosis drug-induced hepatotoxicity in a Chinese Han population.
    Lu L; Tao B; Wei H; Chen H; He X; Pan H; Yang M; Yi H; Tang S
    J Gene Med; 2019 Jun; 21(6):e3096. PubMed ID: 31066138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients.
    An HR; Wu XQ; Wang ZY; Zhang JX; Liang Y
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):535-43. PubMed ID: 22506592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2C9, GSTM1, GSTT1 and NAT2 genetic polymorphisms on DNA damage in workers occupationally exposed to organophosphate pesticides.
    Singh S; Kumar V; Singh P; Banerjee BD; Rautela RS; Grover SS; Rawat DS; Pasha ST; Jain SK; Rai A
    Mutat Res; 2012 Jan; 741(1-2):101-8. PubMed ID: 22108250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
    Yang JJ; Huang CH; Liu CE; Tang HJ; Yang CJ; Lee YC; Lee KY; Tsai MS; Lin SW; Chen YH; Lu PL; Hung CC
    PLoS One; 2014; 9(9):e106141. PubMed ID: 25184238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
    Suvichapanich S; Fukunaga K; Zahroh H; Mushiroda T; Mahasirimongkol S; Toyo-Oka L; Chaikledkaew U; Jittikoon J; Yuliwulandari R; Yanai H; Wattanapokayakit S; Tokunaga K
    Pharmacogenet Genomics; 2018 Jul; 28(7):167-176. PubMed ID: 29781872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
    Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.
    Kim SH; Kim SH; Yoon HJ; Shin DH; Park SS; Kim YS; Park JS; Jee YK
    Eur J Clin Pharmacol; 2011 Feb; 67(2):121-7. PubMed ID: 20941486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.
    Zielińska E; Niewiarowski W; Bodalski J; Rebowski G; Skretkowicz J; Mianowska K; Sekulska M
    Pharm World Sci; 1998 Jun; 20(3):123-30. PubMed ID: 9618736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole.
    Martínez C; Andreu I; Amo G; Miranda MA; Esguevillas G; Torres MJ; Blanca-López N; Blanca M; García-Martín E; Agúndez JA
    Biochem Pharmacol; 2014 Dec; 92(3):457-66. PubMed ID: 25241292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomewide Association Study Confirming the Association of
    Suvichapanich S; Wattanapokayakit S; Mushiroda T; Yanai H; Chuchottawon C; Kantima T; Nedsuwan S; Suwankesawong W; Sonsupap C; Pannarunothai R; Tumpattanakul S; Bamrungram W; Chaiwong A; Mahasirimongkol S; Mameechai S; Panthong W; Klungtes N; Munsoo A; Chauychana U; Maneerat M; Fukunaga K; Omae Y; Tokunaga K
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genotype and phenotype polymorphisms of NAT2 and CYP2E1 in the Han Chinese pediatric population].
    Liu F; Miao Q; Jiao WW; Xiao J; Sun L; Shen C; Wu XR; Shen D; Yin QQ; Shen AD
    Zhongguo Dang Dai Er Ke Za Zhi; 2012 May; 14(5):353-8. PubMed ID: 22613106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
    Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-Chapoñan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
    Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acetyltransferase 2 (NAT2) genetic variation and the susceptibility to noncardiac gastric adenocarcinoma in Taiwan.
    Chang CH; Huang YS; Perng CL; Lin HC
    J Chin Med Assoc; 2016 Mar; 79(3):105-10. PubMed ID: 26617241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.